

# Qualitative evaluation of mobile cancer apps with particular attention to the target group, content, and advertising

Cathleen Böhme<sup>1</sup>  · Marc Baron von Osthoff<sup>1</sup> · Katrin Frey<sup>2</sup> · Jutta Hübner<sup>1</sup>

Received: 4 September 2017 / Accepted: 10 October 2017 / Published online: 19 October 2017  
© Springer-Verlag GmbH Germany 2017

## Abstract

**Purpose** Medical apps are gaining importance rapidly. Also in the field of cancer care, apps are offered. Yet, so far little is known with respect to their quality.

**Methods** In a pilot phase we developed a rating tool based on formal and content-related criteria for the assessment of cancer apps. We used this instrument on cancer apps available in the App Store (iOS) concerning breast, prostate and colorectal cancer. The results were stratified according to target group, content and advertising.

**Results** We assessed 41 mobile cancer apps. Six apps (14.63%) scored very high, fifteen apps (36.59%) high, seventeen apps (41.46%) were deficient, and three apps (7.32%) were insufficient. The largest group of apps represents those apps with the “deficient” rating. The very good to good apps had reliable sources, a concrete intent/ purpose in their app description, and a strict distinction of scientific content and advertisement. Apps with the predicates “deficient” or “insufficient” had particularly poor ratings, e.g. in the sub-scales “information on sources” and “data protection”.

**Conclusions** Almost half of the tested apps were deficient or insufficient. In order to improve safety of patients using apps, some regulation seems mandatory. Putting apps under the legislation for medical products might be one way to better regulate and control quality. Second, efforts should focus on the development of checklists that make it easier for patients to search for suitable cancer apps.

**Keywords** Mobile apps · Application · Cancer · Oncology · Rating tool

## Introduction

Patients are confronted with complex information regarding their illness, treatment decisions or alternative options, and their side effects (Maddock et al. 2011). The patients as well as their caregivers need trustworthy online information in coping with their cancer. Yet, information is often difficult to understand and patients do not always have the possibility to directly address the physician in charge. Accordingly, they need other available and trustworthy sources of information.

Moreover, patients are asked to participate in joint decision-making and to take on responsibilities. For this, the need for sufficient information and a thorough understanding are fundamental (Liebl et al. 2015). Already today, with longer duration of the disease and cancer becoming more and more a chronic disease, many patients become experts in managing their illness by accessing online information and arranging their own care with the help of clinicians (Maddock et al. 2011).

Mobile Health (mHealth) is an innovative and growing field, which is increasingly being used for patient care. With the help of mobile devices like smart phones and tablets and with apps specifically developed for mobile

✉ Jutta Hübner  
jutta.huebner@med.uni-jena.de

Cathleen Böhme  
boehmecathleen@web.de

Marc Baron von Osthoff  
m@osthoff.de

Katrin Frey  
kfrey@kliniken-mtk.de

<sup>1</sup> Klinik für Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747 Jena, Germany

<sup>2</sup> Klinik für Orthopädie und Unfallchirurgie, Kliniken des Main Taunus Kreises GmbH Bad Soden, Bad Soden am Taunus, Germany

devices, cancer patients can get the information fast and at any time. This information includes: prevention, diagnostics, treatments, and therapy options.

While the authors of the study “Chancen und Risiken von Gesundheits-Apps” (Chances and Risks of Health Apps) conclude that health apps have the potential to effectively support the self-management of chronically ill people and to enlarge the treatment adherence, much information is false and/or not actual (Collado-Borrell et al. 2016). In fact, there is a need to enforce the transparency and implement an independent review of mHealth applications in oncology (Brouard et al. 2016). Yet, the CHARISMHA study reported that there is still no comprehensive and valid guidance for assessing the trustworthiness of health apps (Albrecht 2016).

When looking for trustworthy health information on the Internet, quality seals can help to assess the quality of information. Afgis (2013) and HONcode (2017) are institutions committed to the certification of health websites. They also promote the development and dissemination of quality standards for health information in other areas, such as health apps.

Other tools for the evaluation of patient information exist as the DISCERN (2009) instrument which may be used by the patient visiting a website. Moreover, organisations as the German Network for Evidence Based Medicine have published recommendations how to convey high-quality information for lay people in medical care (Steckelberg et al. 2005).

For patients with cancer it is not always easy to identify valuable apps. The search is tedious because very few cancer apps are hidden in long hit lists. Most apps are in foreign languages, without reference to cancer, or exclusively for use by medical professionals (HealthOn 2017). Transparent information about purpose, content, and scientific validation of the app is required. Accordingly, the aim of the present study was to gain data on the quality of apps for cancer patients using a standardised instrument.

## Materials and methods

### Description of the standardized questionnaire

In a first step we searched the literature for a validated instrument to assess medical apps. We only found one instrument: “Mobile app rating scale: a new tool for assessing the quality of health mobile apps” (MARS) (Stoyanov et al. 2015). This questionnaire provides a multidimensional and reliable app quality rating scale.

The parameters of the questionnaire are as follows:

- Interactivity of the app, individualization and degree of involvement of the user and his social environment (engagement, 5 questions).
- Functionality of the app, handling and ease of use (functionality, 4 questions).
- Attractive presentation of the app, visual imagery that is likable and offers an intuitive handling (aesthetics, 3 questions).
- Quality and presentation of information, credibility of the sources (information, 7 questions).
- Assessment of the subjective quality (recommendations, etc. four questions).
- Subjectively felt effect of the app concerning knowledge, attitude, intention of the user, etc. (6 questions).

MARS was developed for the evaluation of health apps in general (Stoyanov et al. 2015). As it did not perfectly meet our requirements, due to the lack of items evaluating quality of content, we decided to add items from other instruments. Criteria from MARS (Stoyanov et al. 2015) that were irrelevant for cancer patients were removed.

In order to assess the quality of websites on cancer, the working group Prevention and Integrative Oncology of the German Cancer Society (GCS) developed an instrument that comprises formal and content-related criteria (Liebl et al. 2015). The scientific basis for this instrument was criteria for evidence-based patient information from other instruments or manuals:

- Afgis criteria (2013).
- HONcode (2017).
- DISCERN (2009).
- Criteria for evidence-based patient information (Steckelberg et al. 2005).
- Manual patient information: recommendations for the creation of evidence-based patient information (Pubmed/Medline (NLM) 12. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ) 2006).

In order to combine MARS with the GCS instrument, criteria from MARS that focused on gamification and entertainment were removed (gamification, strategies to increase engagement, performance, graphics, and visual appeal). Furthermore, for the rating by scientists we removed the rating on subjective quality. Finally, we removed some items concerning likeliness to change attitudes, motivation or behaviour as evidence-based patient information aims at the provision of information and not at directing the patient in a certain direction.

Formal and content-related criteria from the GCS instrument applicable to apps were added. Especially the items in section “information” were specified and expanded.

We added following subscales:

- Visual appeal.
- Purpose of the information.
- Separation of content and commercials.
- Complementarity.
- Requirements with regards to information.
- No statement to sections without safe information.
- Detailed information on therapy methods.
- Statements refer to patient issues.
- Additional material (material for the doctor–patient communication).
- Use of a language that enhances participation.
- Information on sources.
- Data protection.
- Findings about the presentation of numbers and results are being considered.

The questionnaire is divided into three sections (engagement, aesthetics, and information) and includes 22 aspects to be assessed:

- The first section includes the subscales interactivity and target group: does it allow user input, provide feedback, contain prompts, and is the app content appropriate for the target audience?
- Layout and visual appeal are the subscales of the second category.
- Most of the additions relate to the third section, for example purpose of the information, requirements with regard to information, detailed information on therapy methods and data protection.

The detailed complete contents of the questionnaire are shown in Table 1.

In a pilot study, we evaluated ten mobile apps in the field of oncology concerning their quality to assess the feasibility of assessing apps with the new instrument (Böhme et al. 2017).

### Selection of the mobile applications and data collection

A comprehensive search was started in the Apple App Store between April 6, 2017 and April 17, 2017. The search was performed in the category “Medicine” available in the store.

We decided to include apps that were dedicated to the most common types of cancer for women (breast cancer), men (prostate cancer), and both genders (colorectal cancer). Furthermore, we only selected apps which were free of charge.

### Assessment of the apps

The selected apps were assessed by three people (two doctors, one computer scientist) using a three-step Likert scale:

**Table 1** Categories and subscales of the questionnaire

Category	Subscale
Engagement	Interactivity Target group
Aesthetics	Layout Visual appeal
Information	Accuracy of app description Purpose of the information Separation of content and commercials Goals Complementarity Requirements with regards to information No statement to sections without safe information Detailed information on therapy methods Statements refer to patient issues Quantity of information Visual information Additional material (material for the doctor-patient communication) Use of a language that enhances participation Credibility Information on sources Data protection Evidence base Findings about the presentation of numbers and results is being considered

1 = the criteria were fully met

2 = the criteria were partly met

3 = the criteria were not met or only met insufficiently

These scientists did not get to know the answers of the colleagues before they finished their rating.

The results of the three authors were summarised and added up as arithmetic mean. The resulting means were coded as quality according to the following list:

- arithmetic mean 1.00–1.50 means “very good”,
- arithmetic mean 1.51–2.00 means “good”,
- arithmetic mean 2.01–2.50 means “deficient”,
- arithmetic mean 2.51–3.00 means “insufficient”.

In addition to evaluating the apps through the developed questionnaire, we also assessed the following features:

- target group (general population, patients or healthcare professionals),
- content (teaching and information, screening, patient support, congress, or glossary),
- including advertising or no advertising.

**Results**

**Description of cancer-related applications**


In the Apple App Store a total of 203 mobile applications dedicated to breast cancer ( $n = 100$ ), prostate cancer ( $n = 83$ ), and colorectal cancer ( $n = 20$ ) were identified. Out of these 203 apps a total of 115 apps were free of charge, of which 61 apps were in the category “medicine”. Five apps were doublets and two apps were exclusively in French, leaving 54 apps for assessment.

$N = 13$  mobile applications could not be rated for the following reasons:

- lack of availability ( $n = 2$ ),
- technical error ( $n = 6$ ),
- limited access ( $n = 5$ ).

Therefore, 41 apps were left for evaluation by the questionnaire. This selection process is shown in Fig. 1.

**Fig. 1** Selection process of breast cancer, prostate cancer, and colorectal cancer applications



Considering the final 41 apps, the target groups were equally divided with a third addressing patients, health people or healthcare professionals, respectively (Table 1). With respect to the content most apps were focused on teaching and information (76%,  $n = 31$ ), and nearly 90% ( $n = 36$ ) included no advertising (Fig. 2).


**Evaluation of the apps using the developed questionnaire**

The assessment of any chosen apps by the three independent scientists led to homogenous results. The results are presented in Table 2.

Six apps (14.6%) scored very high, 15 apps (36.6%) had good results, 17 apps (41.5%) were evaluated as deficient, and 3 apps (7.3%) were rated as insufficient. The resulting arithmetic mean of all apps is 1.956 (Table 3).

All apps in the group “very good” to “good” were from reliable sources, had a concrete intent/purpose in their app

**Fig. 2** The characteristics of the apps on breast, prostate and colorectal cancer



**Table 2** Classification of apps according to the arithmetic mean, target group, content, and advertising

No	Name of the app	Engagement	Aesthetics	Information	Arithmetic mean	Target group	Content	Advertising
1	Breast cancer: beyond the shock	1	1	1.537	1.179	Patients	Teaching and information	No advertising
2	iCancer health: cancer care - virtual care at home	1	1	1.759	1.253	General population	Patients support	No advertising
3	Met breast	1	1.5	1.574	1.358	Patients	Teaching and information	No advertising
4	CancerAid—empowering cancer patients and carers	1.167	1.167	1.907	1.414	Patients	Teaching and information	No advertising
5	Owise breast cancer	1	1.167	2.24	1.469	Patients	Teaching and information	No advertising
6	Prostate cancer MiMe	1	1.667	1.796	1.488	Healthcare professionals	Teaching and information	No advertising
7	My prostate cancer manager	1	1.5	2.056	1.519	Patients	Teaching and information	No advertising
8	Breast center	1.167	1.5	1.907	1.525	Patients	Teaching and information	No advertising
9	Cancer genetics	1.667	1.167	1.74	1.525	Healthcare professionals	Teaching and information	No advertising
10	CORAL: prostate cancer risk and survival	1	2	1.722	1.574	Healthcare professionals	Teaching and information	No advertising
11	CPC risk calculator	1.5	1.333	1.926	1.586	Patients	Screening	No advertising
12	NCCN patient guides for cancer	2	1.333	1.5	1.611	Patients	Teaching and information	No advertising
13	Focalyx	1.167	1.5	2.296	1.654	General population	Teaching and information	No advertising
14	Cancer mAPP	2.167	1.5	1.537	1.735	Healthcare professionals	Teaching and information	No advertising
15	Breast cancer treatment	1.5	1.8	1.944	1.748	Patients	Patients support	No advertising
16	Bowel cancer	1.667	1.5	2.185	1.784	General population	Teaching and information	No advertising
17	Prostate Pal 3	1.833	2	2.093	1.975	Patients	Teaching and information	No advertising
18	Bladder Pal 2	1.833	2	2.093	1.975	Patients	Teaching and information	No advertising
19	Brisk breast cancer risk assessment	2	2.167	1.81	1.992	General population	Screening	No advertising
20	Adt	2	1.667	2.315	1.994	Patients	Teaching and information	No advertising
21	Renal and urology news	2.167	2	1.815	1.994	Healthcare professionals	Teaching and information	Others
22	Breast cancer risk visualisation	1.667	2.167	2.185	2.006	General population	Screening	No advertising
23	ECCO CanCer	2.333	2	1.796	2.043	Healthcare professionals	Teaching and information	No advertising
24	FYI: breast cancer	2.333	1.667	2.167	2.056	General population	Teaching and information	No advertising

**Table 2** (continued)

No	Name of the app	Engagement	Aesthetics	Information	Arithmetic mean	Target group	Content	Advertising
25	Predictive tools for breast cancer	2	2	2.278	2.093	Healthcare professionals	Screening	No advertising
26	Capra score	1.833	2.167	2.333	2.111	Patients	Screening	No advertising
27	van der Pas	2.667	1.833	1.87	2.123	Healthcare professionals	Teaching and information	No advertising
28	JGO - journal of gastrointestinal oncology	2.5	2	1.981	2.160	General population	Teaching and information	No advertising
29	Cancer screening	2.5	2.167	1.907	2.191	Healthcare professionals	Teaching and information	No advertising
30	Cancer support	2.333	2.167	2.241	2.247	General population	Teaching and information	No advertising
31	Prostate cancer treatment	2.5	2	2.315	2.272	Patients	Teaching and information	No advertising
32	Breast cancer reference	2.5	2	2.33	2.277	General population	Glossary	No advertising
33	European colorectal congress - ECC 2013	2.5	2	2.352	2.284	Healthcare professionals	Congress	Others
34	Breast centres network	2.667	1.833	2.37	2.290	Patients	Teaching and information	No advertising
35	Reviews in urology	3	2.167	1.926	2.364	Healthcare professionals	Teaching and information	No advertising
36	Cancer news reader—research, drug directory, alternative treatments etc	2.333	2.333	2.444	2.370	General population	Teaching and information	Including advertising
37	Prostate cancer support group gibraltar	2.5	2.167	2.556	2.408	General population	Teaching and information	No advertising
38	Prostate volume and density	2.5	2.167	2.796	2.488	Healthcare professionals	Screening	Including advertising
39	Breast cancer care	2.667	2.5	2.74	2.636	General population	Teaching and information	No advertising
40	Breast cancer treatment and prostate cancer help	2.5	2.667	2.92	2.696	General population	Teaching and information	Including advertising
41	Wallpaper of the salvador gil vernet collection of urology drawings	3	2.5	2.667	2.723	General population	Teaching and information	No advertising

description, and a strict distinction of scientific content and advertisement.

Apps with the predicates “deficient” or “insufficient” had particularly poor ratings in the following subscales of the questionnaire:

- Requirements with respect to information.
- Statement to sections without safe information.
- Detailed information on therapy methods.

- Information on sources.
- Data protection.


### Quality of the apps and target group

Considering the quality of the apps for the different target groups (Fig. 3), the ranking for apps that were dedicated to the target group “patients” were better than the overall

**Table 3** Evaluation of the 18 subscales of category “Information” for the three target groups

	General population	Patients	Healthcare professionals
1. Accuracy of app description	1.48	1.27	1.19
2. Purpose of the information	1.48	1.2	1.31
3. Separation of content and commercials	1.29	1.02	1.42
4. Goals	1.74	1.36	1.67
5. Complementarity: is the app a help for “shared-decisions-making”	2.62	2.13	2.47
6. Requirements with regards to information	2.71	2.47	1.56
7. No statement to sections without safe information	2.55	2.42	1.56
8. Detailed information on therapy methods	2.86	2.56	2.36
9. Statements refer to patient issues	2.09	1.51	1.92
10. Quantity of information	2.31	1.82	1.89
11. Visual information	2.45	2.02	2.11
12. Additional material (material for the doctor–patient communication)	2.74	2.49	2.64
13. Use of a language that enhances participation	2.21	1.84	2.39
14. Credibility: does the app come from a legitimate source	1.93	1.53	1.33
15. Information on sources: references	2.62	2.56	1.67
16. Data protection	2.74	2.09	2.94
17. Evidence base	2.98	2.96	2.86
18. Conclusions of results are included	2.74	2.42	1.72

**Fig. 3** Quality of apps for the target groups



average distribution with 4 apps (26.7%) being very good and 8 apps (53.3%) good. No app was insufficient. In contrast, apps of the general population had a much lower scoring with 7 apps (50%) being deficient, and 3 apps (21.4%) being insufficient.

The results for apps for the target group “healthcare professionals” were heterogeneous with only 1 (8.3%) very good app and 7 (58.3%) deficient apps.

In a subsequent step we assigned the 18 subscales of category “Information” to the three target groups.

For apps for all three target groups the results in subscales “Accuracy of app description”, “Purpose of the information”, and “Separation of content and commercials” are almost homogenous.

The apps for the target group healthcare professionals received good scorings in the subscales “Requirements with regards to information”, “ No statement to sections without safe information”, “ Information on sources: references”, and “Conclusions of results are included”. Those for the target groups general population and patients



only received deficient or insufficient scores for the same subscales.

Apps for all three target groups received only deficient or insufficient scores in the subscales “Complementarity” and “Data protection”.

## Discussion

In this study, we rated a total of 41 cancer apps dedicated to cancer types “breast cancer”, “prostate cancer”, and “colorectal cancer” using a questionnaire consisting of content-related and formal criteria. The evaluations by three independent scientists were homogeneous. The questionnaire specifically developed for the rating of cancer apps proved to be very suitable (Böhme et al. 2017). Yet, the reliability of the questionnaire was not tested, which is one limitation of our study.

The results of the present study show that half of the apps are good to very good (14.6% very good, 36.59% good). Only 7% were insufficient.

“Cancer genetics”, an app which provides clinicians with streamlined risk assessment and referral guidance for hereditary cancer, has been awarded MHRA certification as a Class 1 medical device (Medicines and Healthcare products Regulatory Agency 2017). Licences for medicines are granted only when a product meets high standards of safety and quality and works for the purpose intended. In our rating the arithmetic mean was 1.525, which was significantly better than the resulting arithmetic mean of all apps of 1.956. For this app criteria were fully met for 11 out of 22 subscales, e.g., requirements with regard to information, statements refer to patient issues, credibility, evidence base.

The app “Breast cancer: Beyond the Shock” had the best result in the study and was developed by the National Breast Cancer Foundation, a self-help group. The German Cancer Society also came to similar conclusions when rating websites using the same formal and content criteria. In their study the best scores were achieved among others by three self-help groups (Liebl et al. 2015). Many cancer-related self-help groups were already assessed on the basis of formal criteria and received a quality seal (Afgis 2017).

In contrast in our pilot study using apps from the Google Store, 40% were rated as insufficient (Böhme et al. 2017). Due to the low number of apps in the pilot study, these data must be considered with caution. Yet, health care professionals should know that apps offered in the two stores are different and that there might be gaps in quality. Moreover, there was a difference between both stores with respect to advertisement. The apps with poor to insufficient rating had no distinction between scientific content and advertisement.

Particularly noteworthy is that the apps offer little to no support in shared decision making for both patients and the

general population. In fact the subscale “Complementarity” is almost always rated low. Yet, this feature is not easy to realise in the concise form of an app as much information must be presented and the user should be encouraged to weigh different arguments. One solution is used in apps for healthcare professionals, which offers scientific sources in most cases and includes conclusions of results.

Another deficit is the low ranking for “Data protection”. With increasing complexity of apps, more and more data on the user will be entered to increase tailoring and interactivity and data protection will become a highly relevant topic.

For the usability for patient’s quality criteria the offering of cancer apps is rather unclear due to the size and dynamic development. Inadequate app descriptions without explicit details on content and functionality aggravate searching for suitable and high-quality cancer apps. Currently there are no tools for cancer patients available to facilitate targeted searching of high-quality cancer apps.

Future efforts should focus on the development of guidelines that make it easier for patients to search for suitable cancer apps. Regulation is required in order to prevent these tools from becoming a safety problem instead of an aid for cancer patients.

### Compliance with ethical standards

**Conflict of interest** The authors declare no conflict of interest.

**Funding** There was no funding for this study.

**Ethical approval** This article does not contain any studies with human participants performed by any of the authors.

## References

- Afgis EV (2013) Qualitätslogo. <https://www.afgis.de/qualitaetslogo/transparenzkriterien>. Last accessed 11 July 2017
- Afgis EV (2017) Logo-Datenbank. <https://www.afgis.de/qualitaetslogo/aqdb/anbieter>. Last accessed 11 July 2017
- Albrecht U-V (2016) Kapitel Kurzfassung. In: Albrecht U-V (Hrsg), Chancen und Risiken von Gesundheits-Apps (CHARISMHA), Medizinische Hochschule Hannover, 2016, S. 14–47. urn:nbn:de:gbv:084-16040811173. <http://www.digibib.tu-bs.de/?docid=60004>
- Böhme C, von Osthoff MB, Frey K, Hübner J, Canc Educ J (2017) Development of a rating tool for mobile cancer apps: information analysis and formal and content-related evaluation of selected. Cancer Apps. doi:10.1007/s13187-017-1273-9
- Brouard B, Bardo P, Bonnet C, Mounier N, Vignot M, Vignot S (2016) Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools? Ann Med 48(7):509–515. doi:10.1080/07853890.2016.1195010
- Collado-Borrell R, Escudero-Vilaplana V, Ribed-Sanchez A, Ibanez-Garcia S, Herranz-Alonso A, Sanjurjo-Saez M (2016) Smartphone applications for cancer patients; what we know about them? Farmacia hospitalaria: organo oficial de expresion cientifica de



- la Sociedad Espanola de Farmacia Hospitalaria 40(1):25–35. doi:10.7399/fh.2016.40.1.8993
- DISCERN (2009) Das Discern Instrument, [www.discern.org.uk/discern\\_instrument.php](http://www.discern.org.uk/discern_instrument.php). Last accessed 11 July 2017
- HealthOn (2017) Krebs-Apps: Es gibt nicht viele, sie werden kaum genutzt. <https://www.healthon.de/blogs/2017/01/10/krebs-apps-es-gibt-nicht-viele-sie-werden-kaum-genutzt>. Last accessed 11 July 2017
- HONcode (2017) The HONcode of conduct for medical and health Web sites (HONcode). <http://www.hon.ch/HONcode/Patients/Conduct.html>. Last accessed 11 July 2017
- Liebl P, Seilacher E, Koester MJ, Stellamanns J, Zell J, Hubner J (2015) What cancer patients find in the internet: the visibility of evidence-based patient information—analysis of information on German websites. *Oncol Res Treat* 38(5):212–218. doi:10.1159/000381739
- Maddock C, Lewis I, Ahmad K, Sullivan R (2011) Online information needs of cancer patients and their organizations. *Ecancermedicalsecience* 5:235. doi:10.3332/ecancer.2011.235
- Medicines & Healthcare products Regulatory Agency (2017) <http://www.mhra.gov.uk>. Last accessed 11 July 2017
- Pubmed/Medline (NLM) 12 (2006) Ärztliches Zentrum für Qualität in der Medizin (ÄZQ): Manual Patienteninformation Empfehlungen zur Erstellung evidenzbasierter Patienteninformationen. Berlin, ÄZQ. [www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe25.pdf](http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe25.pdf) (äzq Schriftenreihe 25)
- Steckelberg A, Berger B, Köpke S, Heesen C, Mühlhauser I (2005) Kriterien für evidenzbasierte Patienteninformationen. *Z Arztl Fortbild Qualitätssich* 99:343351
- Stoyanov SR, Hides L, Kavanagh DJ, Zelenko O, Tjondronegoro D, Mani M (2015) Mobile app rating scale: a new tool for assessing the quality of health mobile apps. *JMIR mHealth uHealth* 3(1):e27. doi:10.2196/mhealth.3422